Investors Business Daily·Jun 26, 2026
Entertainment Stocks Madison Square Garden, Sphere Rally To New HighsEntertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
Krystal Biotech, Inc.(KRYS)Earnings, Financials & Key Ratios
KRYS•NASDAQ
$368.60
53.9× P/E·Price updated Jul 7, 2026
AboutKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.Show more
- Revenue$389M+33.9%
- EBITDA$168M+131.8%
- Net Income$205M+129.7%
- EPS (Diluted)6.84+128.0%
- Gross Margin92.61%-0.5%
- EBITDA Margin43.13%+73.1%
- Operating Margin41.45%+83.3%
- Net Margin52.64%+71.5%
- ROE18.91%+83.0%
KRYS Price & Volume
Krystal Biotech, Inc. (KRYS) stock price & volume — 10-year historical chart
Loading chart...
Commercial Scaling Drives Robust Margin Expansion Trajectory
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Strong
Financial:Fortress
Cash Flow:Robust
Primary Risk:Clinical pipeline execution risk
Key Thesis Takeaways
- Krystal Biotech has successfully transitioned into a self-sustaining commercial entity, evidenced by its 31.9% year-over-year revenue growth in 2026Q1 and the rapid scaling of its STAR-D platform.
- While the company maintains a fortress balance sheet with $501.3 million in cash and negligible debt, investors should monitor the potential for margin compression as the firm expands into more complex inhaled delivery systems.
- The strategic shift toward capital returns, highlighted by $17.0 million in share repurchases, underscores management's confidence in the long-term commercial viability of its rare disease portfolio.
Verdict Logic
the company's transition to a self-sustaining commercial model is supported by a strong 62.9% FCF margin and a healthy liquidity profile of $501.3 million in cash.
KRYS Growth Metrics
Krystal Biotech, Inc. (KRYS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM25.15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM81.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.81%
Return on Capital
10 Years-14.89%
5 Years-7.06%
3 Years1.88%
Last Year14.77%
KRYS Recent Earnings
Krystal Biotech, Inc. (KRYS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$1.83+26.2%
$1.45
Rev
$116M+3.8%
$112M
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$1.70+4.9%
$1.62
Rev
$107M+1.7%
$105M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$2.66+137.5%
$1.12
Rev
$98M-7.1%
$105M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.29+19.4%
$1.08
Rev
$96M+0.7%
$95M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $1.83vs $1.45+26.2% | $116Mvs $112M+3.8% |
| Q1 2026 | Feb 17, 2026 | $1.70vs $1.62+4.9% | $107Mvs $105M+1.7% |
| Q4 2025 | Nov 3, 2025 | $2.66vs $1.12+137.5% | $98Mvs $105M-7.1% |
| Q3 2025 | Aug 4, 2025 | $1.29vs $1.08+19.4% | $96Mvs $95M+0.7% |
Based on last 12 quarters of dataView full earnings history →
Latest KRYS News
Recent stock market news and headlines for Krystal Biotech, Inc. (KRYS)
MarketBeat·Jun 23, 2026
3 Biotech Firms With Major Potential Catalysts in the Coming MonthsAs Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
MarketBeat·Jun 21, 2026
3 Biotech Firms With Major Potential Catalysts in the Coming MonthsAs Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.
The Motley Fool·Jun 18, 2026
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside AheadModerna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
Peers Comparison
Key metrics vs top competitors for Krystal Biotech, Inc. (KRYS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $368.60 | $10.87B | 53.89 | 33.94% | 52.64% | 18.91% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — |
Compare KRYS vs Peers
Krystal Biotech, Inc. (KRYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KRYS SEC Filings & Documents
Krystal Biotech, Inc. (KRYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Feb 17, 2026·SEC
Material company update
Jan 12, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when KRYS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KRYS Frequently Asked Questions
Krystal Biotech, Inc. (KRYS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Krystal Biotech, Inc.'s revenue?
Krystal Biotech, Inc. (KRYS) reported $417.3M in revenue for fiscal year 2025.
How fast is Krystal Biotech, Inc. growing?
Krystal Biotech, Inc. (KRYS) grew revenue by 33.9% over the past year. This is strong growth.
Is KRYS profitable?
Yes, Krystal Biotech, Inc. (KRYS) is profitable, generating $225.0M in net income for fiscal year 2025 (52.6% net margin).
Dividend & Returns
What is KRYS's return on equity?
Krystal Biotech, Inc. (KRYS) has a return on equity (ROE) of 18.9%. This is reasonable for most industries.
What is Krystal Biotech, Inc.'s free cash flow?
Krystal Biotech, Inc. (KRYS) generated $237.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.